N-Acetyl cysteine may support dopamine neurons in Parkinson's disease: Preliminary clinical and cell line data

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Monti, Daniel A ^a   Zabrecky, George ^a   Kremens, Daniel ^b   Liang, Tsao Wei ^b   Wintering, Nancy A ^a   Cai, Jingli ^b   Wei, Xiatao ^b   Bazzan, Anthony J ^a   Zhong, Li ^a   Bowen, Brendan ^a   Intenzo, Charles M ^b   Iacovitti, Lorraine ^b   Newberg, Andrew B ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; DOPAMINE; DOPAMINE TRANSPORTER; ROTENONE; ANTIOXIDANT; NEUROPROTECTIVE AGENT; NEUROTOXIN;

ADULT; ARTICLE; CAUDATE NUCLEUS; CELL PROTECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG EFFICACY; DRUG MECHANISM; EMBRYO; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MESENCEPHALON; MIDDLE AGED; NERVE CELL; PARKINSON DISEASE; PILOT STUDY; PROTEIN BINDING; PUTAMEN; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE; AGED; ANTAGONISTS AND INHIBITORS; CELL DIFFERENTIATION; CELL SURVIVAL; CYTOLOGY; DIAGNOSTIC IMAGING; DOPAMINERGIC NERVE CELL; DRUG EFFECTS; HUMAN EMBRYONIC STEM CELL; METABOLISM; PATHOLOGY; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY-COMPUTED TOMOGRAPHY; TISSUE CULTURE TECHNIQUE;

ACETYLCYSTEINE; AGED; ANTIOXIDANTS; CAUDATE NUCLEUS; CELL DIFFERENTIATION; CELL SURVIVAL; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINERGIC NEURONS; FEMALE; HUMAN EMBRYONIC STEM CELLS; HUMANS; MALE; MESENCEPHALON; MIDDLE AGED; NEUROPROTECTIVE AGENTS; NEUROTOXINS; PARKINSON DISEASE; PILOT PROJECTS; PUTAMEN; ROTENONE; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY COMPUTED TOMOGRAPHY; TISSUE CULTURE TECHNIQUES;

EID: 84976384948     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0157602     Document Type: Article

References (61)

1. Korell M, Tanner CM. Epidemiology of Parkinson's disease: An overview In: Ebadi MPR, editor. Parkinson's Disease. Boca Raton, FL: CRC Press. 2005, pp 39-50.
2. Šumec R, Filip P, Sheardová K, Bareš M. Psychological benefits of nonpharmacological methods aimed for improving balance in Parkinson's disease: A systematic review. Behav Neurol. 2015; 2015:620674. doi: 10.1155/2015/620674 PMID: 26236107
3. Zigmond MJ, Smeyne RJ. Exercise: is it a neuroprotective and if so, how does it work? Parkinsonism Relat Disord. 2014; 20 Suppl 1:S123-127. doi: 10.1016/S1353-8020(13)70030-0 PMID: 24262162
4. Weber CA, Ernst ME. Antioxidants, supplements, and Parkinson's disease. Ann Pharmacother. 2006; 40:935-938. PMID: 16622156
5. Chao J, Leung Y, Wang M, Chang RC. Nutraceuticals and their preventive or potential therapeutic value in Parkinson's disease. Nutr Rev. 2012; 70(7):373-386. doi: 10.1111/j.1753-4887.2012.00484.x PMID: 22747840
6. Sies H, Cadenas E. Oxidative stress: damage to intact cells and organs. Philos Trans R Soc Lond B Biol Sci. 1985; 311:617-631. PMID: 2869521
7. Chinta SJ, Andersen JK. Redox imbalance in Parkinson's disease. Biochimica et Biophysica Acta. 2008; 1780: 1362-1367. doi: 10.1016/j.bbagen.2008.02.005 PMID: 18358848
8. Olsson B, Johansson M, Gabrielsson J, Bolme P. Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. Eur J Clin Pharmacol. 1988; 34:77-82. PMID: 3360052
9. Borgström L, Kågedal B, Paulsen O. Pharmacokinetics of N-acetylcysteine in man. Eur J Clin Pharmacol. 1986; 31:217-222. PMID: 3803419
10. Holmay MJ, Terpstra M, Coles LD, Mishra U, Ahlskog M, Öz G, et al. N-acetylcysteine boosts brain and blood glutathione in Gaucher and Parkinson diseases. Clin Neuropharmacol. 2013; 36(4):103-106. doi: 10.1097/WNF.0b013e31829ae713 PMID: 23860343
11. Schulz JB, Lindenau J, Seyfried J, Dichgans J. Glutathione, oxidative stress and neurodegeneration. Eur J Biochem. 2000; 267(16):4904-4911. PMID: 10931172
12. Cai J, Schleidt S, Pelta-Heller J, Hutchings D, Cannarsa G, Iacovitti L. BMP and TGF-β pathway mediators are critical upstream regulators of Wnt signaling during midbrain dopamine differentiation in human pluripotent stem cells. Dev Biol. 2013; 376:62-73. doi: 10.1016/j.ydbio.2013.01.012 PMID: 23352789
13. Jaber M. Jones S. Giros B. Caron MG. The dopamine transporter: a crucial component regulating dopamine transmission. Movement Dis. 1997; 12:629-633. PMID: 9380041
14. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. Hyperlocomotion and indifference to cocaine and methamphetamine in mice lacking the dopamine transporter. Nature. 1996; 379:606-612.
15. Frost JJ, Rosier AJ, Reich SG, Smith JS, Ehlers MD, Snyder SH, Ravert HT, Dannals RF. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked decline in mild Parkinson's disease. Ann Neurol. 1993; 34:423-431. PMID: 8363363
16. Shoemaker H, Pimoule C, Arbilla S, Scatton B, Javoy-Agid F, Langer SZ. Sodium dependent [3H] cocaine binding associated with dopamine uptake sites in the rat striatum and human putamen decrease after dopaminergic denervation and in Parkinson's disease. Naunyn-Schmiedeberg's Arch Pharmacol. 1985; 239:227-235.
17. Innis RB, Seibyl JP, Scanley BE, Laruelle M, Abi-Dargham A, Wallace E, et al. Single-photon emissioncomputed tomography imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci USA. 1993; 90:11965-11969. PMID: 8265656
18. Seibyl JP, Marek K, Sheff K, Zoghbi S, Baldwin RM, Charney DS, et al. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. J Nucl Med. 1998; 39:1500-1508. PMID: 9744331
19. Eshuis SA, Jager PL, Maguire RP, Jonkman S, Dierckx RA, Leenders KL. Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls. Eur J Nucl Med Mol Imaging. 2009; 36:454-462. doi: 10.1007/s00259-008-0989-5 PMID: 19037637
20. Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG, et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997; 62:133-140. PMID: 9048712
21. Wang J, Zuo CT, Jiang YP, Guan YH, Chen ZP, Xiang JD, et al. 18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson's disease in various Hoehn & Yahr stages. J Neurol. 2007; 254:185-190. PMID: 17334953
22. Kriks S, Shim J-W, Piao J, Ganat YM, Wakeman DR, Xie Z, et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 2011; 480 (7378):547-551. doi: 10.1038/nature10648 PMID: 22056989
23. Brunswick DJ, Amsterdam JD, Mozley PD, Newberg AB. Greater availability of brain dopamine transporters in major depression shown by [(99m)Tc]TRODAT-1 SPECT imaging. Amer J Psych. 2003; 160:1836-1841.
24. Koch W, Unterrainer M, Xiong G, Bartenstein P, Diemling M, Varrone A, et al. Extrastriatal binding of [(123)I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls. Eur J Nucl Med Mol Imaging. 2014; 41:1938-1946. doi: 10.1007/ s00259-014-2785-8 PMID: 24806112
25. García-Gómez FJ, García-Solís D, Luis-Simón FJ, Marín-Oyaga VA, Carrillo F, Mir P, et al. Elaboration of the SPM template for the standardization of SPECT images with 123I-Ioflupane. Rev Esp Med Nucl Imagen Mol. 2013; 32(6):350-356.
26. Sies H, Cadenas E. Oxidative stress: damage to intact cells and organs. Philos Trans R Soc Lond B Biol Sci. 1985; 311:617-631. PMID: 2869521
27. Scherman D, Desnos C, Darchen F, Pollak P, Javoy-Agid F, Agid Y. Striatal dopamine deficiency in Parkinson's disease: role of aging. Ann Neurol. 1989; 26: 551-557. PMID: 2817829
28. Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology. 1996; 47:S161-S170. PMID: 8959985
29. Jenner P. Presymptomatic detection of Parkinson's disease. J Neural Transm Suppl. 1993; 40: 23-36.
30. Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology. 1996; 47:S161-S170. PMID: 8959985
31. Braak H, Braak E. Pathoanatomy of Parkinson's disease. J Neurol. 2000; 247 (Suppl 2): II3-10. PMID: 10991663
32. Paxinou E, Chen Q, Weisse M, Giasson BI, Norris EH, Rueter SM, et al. Induction of alpha-synuclein aggregation by intracellular nitrative insult. J Neurosci. 2001; 21:8053-8061. PMID: 11588178
33. Ischiropoulos H, Beckman JS. Oxidative stress and nitration in neurodegeneration: cause, effect, or association? J Clin Invest. 2003; 11:163-169.
34. Uversky VN, Li J, Fink AL. Metal-triggered structural transformations, aggregation, and fibrillation of human α-synuclein. J Biol Chem. 2001; 23:44284-44296.
35. Hashimoto M, Hsu LJ, Xia Y, Takeda A, Sisk A, Sundsmo M, Masliah E. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport. 1999; 10:717-721. PMID: 10208537
36. Thomas MP, Chartrand K, Reynolds A, Vitvitsky V, Banerjee R, Gendelman HE. Ion channel blockade attenuates aggregated alpha synuclein induction of microglial reactive oxygen species: relevance for the pathogenesis of Parkinson's disease. J Neurochem. 2007; 100:503-519. PMID: 17241161
37. Offen D, Ziv I, Sternin H, Melamed E, Hochman A. Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease. Exp Neurol. 1996 Sep; 141 (1):32-9. PMID: 8797665
38. Jiang Y, Rumble JL, Gleixner AM, Unnithan AS, Pulugulla SH, Posimo JM, et al. N-Acetyl cysteine blunts proteotoxicity in a heat shock protein-dependent manner. Neuroscience. 2013; 255:19-32. doi: 10.1016/j.neuroscience.2013.09.049 PMID: 24096134
39. Unnithan AS, Jiang Y, Rumble JL, Pulugulla SH, Posimo JM, Gleixner AM, et al. N-Acetyl cysteine prevents synergistic, severe toxicity from two hits of oxidative stress. Neurosci Lett. 2014; 560:71-76. doi: 10.1016/j.neulet.2013.12.023 PMID: 24361774
40. Ratan RR, Murphy TH, Baraban JM. Macromolecular synthesis inhibitors prevent oxidative stressinduced apoptosis in embryonic cortical neurons by shunting cysteine from protein synthesis to glutathione. J Neurosci. 1994; 17:4385-4392.
41. Clark J, Clore EL, Zheng K, Adame A, Masliah E, Simon DK. Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in α-synuclein over-expressing mice. PLoS One. 2010; 5(8):e12333. doi: 10. 1371/journal.pone.0012333 PMID: 20808797
42. Aoki E, Yano R, Yokoyama H, Kato H, Araki T. Role of nuclear transcription factor kappa B (NF-kappaB) for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine)-induced apoptosis in nigral neurons of mice. Exp Mol Pathol. 2009; 86: 57-64. doi: 10.1016/j.yexmp.2008.10.004 PMID: 19027004
43. Sha D, Chin LS, Li L. Phosphorylation of parkin by Parkinson disease linked kinase PINK1 activates parkin E3 ligase function and NF-kappaB signaling. Hum Mol Genet. 2010; 19:352-363. doi: 10.1093/ hmg/ddp501 PMID: 19880420
44. Bagh MB, Maiti AK, Jana S, Banerjee K, Roy A, Chakrabarti S. Quinone and oxyradical scavenging properties of N-acetylcysteine prevent dopamine mediated inhibition of Na+, K+-ATPase and mitochondrial electron transport chain activity in rat brain: implications in the neuroprotective therapy of Parkinson's disease. Free Radic Res. 2008; 42: 574-581. doi: 10.1080/10715760802158430 PMID: 18569015
45. Chandramani Shivalingappa P, Jin H, Anantharam V, Kanthasamy A, Kanthasamy A. N-acetyl cysteine protects against methamphetamine-induced dopaminergic neurodegeneration via modulation of redox status and autophagy in dopaminergic cells. Parkinsons Dis. 2012:424285. doi: 10.1155/2012/424285 PMID: 23056996
46. Martínez-Banaclocha M, Hernández AI, Martínez N, Ferrándiz ML. N-acetylcysteine protects against age-related increase in oxidized proteins in mouse synaptic mitochondria. Brain Res. 1997; 762: 256-258. PMID: 9262186
47. Vina J, Romero FJ, Saez GT, Pallardó FV. Effects of cysteine and N-acetyl cysteine on GSH content of brain of adult rats. Experientia. 1983; 39: 164-165. PMID: 6832291
48. Martínez-Banaclocha M, Martínez N, Hernández, Ferrándiz ML. Hypothesis: can N-acetylcysteine be beneficial in Parkinson's disease? Life Sci. 1999; 64:1253-1257. PMID: 10227580
49. Martínez-Banaclocha M. N-acetylcysteine elicited increase in complex I activity in synaptic mitochondria from aged mice. Implications for treatment of Parkinson's disease. Brain Res. 2000; 859: 173-175. PMID: 10720628
50. Perry TL, Yong VW, Clavier RM, Jones K, Wright JM, Foulks JG, et al. Partial protection from the dopaminergic neurotoxin Nmethyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse. Neurosci Lett. 1985; 60: 109-114. PMID: 3877260
51. Sharma A, Kaur P, Kumar V, Gill KD. Attenuation of 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine induced nigro-striatal toxicity in mice by N-acetyl cysteine. Cell Mol Biol. 2007; 53: 48-55. PMID: 17519111
52. Medina S, Martínez-Banaclocha M, Hernanz A. Antioxidants inhibit the human cortical neuron apoptosis induced by hydrogen peroxide, tumor necrosis factor alpha, dopamine and beta-amyloid peptide 1-42. Free Radic Res. 2002; 36: 1179-1184. PMID: 12592670
53. Hauser RA, Lyons KE, McClain T, Carter S, Perlmutter D. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Mov Disord. 2009; 24:979-983. doi: 10.1002/mds. 22401 PMID: 19230029
54. Newberg AB, Amsterdam JD, Wintering N, Shults J. Low brain serotonin transporter binding in major depressive disorder. Psychiatry Res. 2012; 202:161-167. doi: 10.1016/j.pscychresns.2011.12.015 PMID: 22698760
55. Lehto SM, Tolmunen T, Kuikka J, Valkonen-Korhonen M, Joensuu M, Saarinen PI, et al. Midbrain serotonin and striatum dopamine transporter binding in double depression: a one-year follow-up study. Neurosci Lett. 2008; 441:291-295. doi: 10.1016/j.neulet.2008.06.042 PMID: 18588943
56. Goetz CG, Wuu J, McDermott MP, Adler CH, Fahn S, Freed CR, et al. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord. 2008; 23(5):690-9. doi: 10.1002/mds.21894 PMID: 18228568
57. Hesse S, Strecker K, Winkler D, Luthardt J, Scherfler C, Reupert A, et al. Effects of subthalamic nucleus stimulation on striatal dopaminergic transmission in patients with Parkinson's disease within one-year follow-up. J Neurol. 2008; 255:1059-1066. doi: 10.1007/s00415-008-0849-z PMID: 18446306
58. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson disease progression. JAMA. 2002; 287:1653-1661. PMID: 11926889
59. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol. 2003; 54:93-101. PMID: 12838524
60. Ahlskog JE, Maraganore DM, Uitti RJ, Uhl GR. Brain imaging to assess the effects of dopamine agonists on progression of Parkinson disease. JAMA. 2002; 288(3):311.
61. Leon AC, Davis LL, Kraemer HC. The role and interpretation of pilot studies in clinical research. J Psych Res. 2011; 45(5), 626-629.